Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
The project is part of the agency’s Resilience Program and will create an additional resilient storage location for rail cars and locomotives that will provide greater ...